RAPID MICRO BIOSYSTEMS (RPID) Company Report

Rapid Micro Biosystems (RPID) notes easing investment sentiment among biopharma customers, with top ROI and strategic projects continuing to be approved, and the trend of reshoring being "real".
The company recently secured a large, multi-system, global order from an existing customer, with revenue recognition for systems expected in Q4 2025, service revenue in H1 2026, and recurring revenue from H2 2026 and beyond.
A co-exclusive distribution agreement with Merck-MilliporeSigma is anticipated to accelerate GrowthDirect sales globally, including new markets like personal care, and improve gross margins through lower procurement costs.
RPID has achieved five consecutive quarters of positive gross margins and expects acceleration in 2026, driven by service volume, the large multi-system order, the Merck partnership, and cost reductions. Product margins are anticipated to be positive in Q4 2025 and all four quarters of 2026.
The company is comfortable with a 20% revenue growth trajectory going forward, aligning with internal targets, supported by existing backlog, the MilliporeSigma contribution, and a strong sales funnel.

Nov 11, 2025, 4:20 PM

Rapid Micro Biosystems Reports Q3 2025 Results and Raises Full-Year Guidance

RPID

Earnings

Guidance Update

New Projects/Investments

Rapid Micro Biosystems reported Q3 2025 revenue of $7.8 million, a 3% increase compared to Q3 2024, marking its 12th consecutive quarter of meeting or beating revenue guidance. Recurring revenue, which includes consumables and annual service contracts, increased 32% year-over-year to $4.8 million.
The company secured a record multi-system order from an existing top 20 global biopharma customer in October, with contributions expected to begin in Q4 2025 and extend into 2026 and beyond.
As a result of strong year-to-date performance and initial contributions from the multi-system order, the full-year 2025 revenue guidance was raised to at least $33 million, including at least 27 GrowthRx system placements.
The collaboration with MilliporeSigma is progressing, with initial GrowthRx system orders in Q3 2025, and an anticipated product supply agreement is expected to lower direct product costs and improve gross margins, with financial benefits starting in the second half of 2026.
Rapid Micro Biosystems ended Q3 2025 with approximately $42 million in cash and investments.

Nov 7, 2025, 1:30 PM

Rapid Micro Biosystems Reports Q3 2025 Results and Raises Full-Year Guidance

RPID

Earnings

Guidance Update

New Projects/Investments

Rapid Micro Biosystems reported Q3 2025 total revenue of $7.8 million, representing a 3% growth compared to the third quarter of 2024, with recurring revenue increasing 32% to $4.8 million.
The company announced a record multi-system order in October 2025 from an existing Top 20 global biopharma customer, with systems to be placed across manufacturing sites in North America, Europe, and Asia Pacific.
Rapid Micro Biosystems raised its full-year 2025 total revenue guidance to at least $33.0 million, which assumes at least 27 Growth Direct system placements.

Nov 7, 2025, 11:03 AM

Rapid Micro Biosystems Announces Q2 2025 Results and New Term Loan Facility

RPID

Earnings

Guidance Update

Debt Issuance

Rapid Micro Biosystems reported Q2 2025 total revenue of $7.3 million, marking a 10% growth compared to Q2 2024, with recurring revenue increasing by 15%.
The company achieved a 4% gross margin in Q2 2025, a seven-percentage point improvement from Q2 2024, and reported a net loss per share of $0.27.
Rapid Micro Biosystems reaffirmed its full-year 2025 total revenue guidance of at least $32.0 million.
The company entered into a five-year, $45 million term loan facility with Trinity Capital Inc., with $20 million funded at close and no financial or liquidity covenants.

Aug 12, 2025, 12:00 AM

Rapid Micro Biosystems Inc Reports Q1 2025 Financial Results

RPID

Earnings

Revenue Acceleration/Inflection

Guidance Update

Revenue increased 28% to $7.2 million in Q1 2025, driven by significant gains in both product and service revenue
Gross margins improved dramatically from a negative 27% to 6%, reflecting effective cost management and operational efficiencies
Service revenue surged 64%, setting a quarterly record
A strategic global Distribution and Collaboration Agreement with MilliporeSigma was announced to support future growth and margin enhancements
Net loss narrowed to $11.3 million with a loss per share of $0.26, indicating improved operational performance
The company reaffirmed its full year 2025 revenue guidance of at least $32 million

May 9, 2025, 12:31 PM

Filings & Transcripts

Recent SEC filings and earnings call transcripts for RPID.

No recent filings or transcripts found for RPID.